icone plus
Contact
Abonnez-vous aux actualités
Reason for request
Renewal of inclusion
Clinical Benefit
Substantial
The actual benefit of DOTAREM remains substantial.
Clinical Added Value
minor
DOTAREM offers a minor improvement in actual benefit (level IV) in terms of safety over gadolinium-based contrast media presenting a high (OMNISCAN, MAGNEVIST) or moderate (MULTIHANCE) risk of nephrogenic systemic fibrosis according to the European Medicines Agency classification.
eNrNWF1v2jAUfedXRHknbrJC6RSoOtauSEVltGjTXiqTXMDM2Kk/KN2vn5PQjk6J2ppa6hvYzrnXvsfnniQ+2ayotwYhCWddPwwOfA9YwlPC5l1/cnPe7PgnvUa8xGu8s8ysC6LI9xKKpez6+WwwBcxk8HN4+RXM8yD8XsOL+XQJiXq2TitCgwssF0Oc5Wu8eM1J6q1ALXja9TOtilEvlkqYLHr3XPyWGU4gRtuR3dnl7eHueIxysFegagniErN5JSgwK8xECwFM9bGCORcPNfl+ssImcgySa5HACKvFSPA1SSGtDDHDVIJVkNl9eg1iTUHlQSrB0TJZSStwvMSbMdwNqpM+NbN9tVHNg2Z4FB51WmHrsNPptK1CiZ2jqq6C2QRKbk2kdtSOELBiWygTaXgbHXfaUdQpBiVaYkq4WcsFoIzqOWESDXmqKVycXkcH4bFZlKEVTzFFCVEghvnPwAxalnnEhcLUUYGJ7D/nqKM4Au5eJFJKZEbxwz5HhQU20+bMceZuI/kOboTRNmrO7D98pilFb8x6slUeRxnnwtbnmqkaATof2x5EnzMFm/qK2mmm2my5SEC+H+wfzqr7xUhPKUls1dHolwapJuNBvTh+UF35giVMhDth+UFYyu/l+wvWLkEcZZ8VmlsJ+lS6sNWyvo+/DBtr+t6ZFjwDZKSMyH0UasBmfF9tMgSvhnqk90dkdmHkeIIp1Fi5pqXiGUo/Ok9nl8bdhSwnKkG/nd3YMu27BvFwXfythCZp94kjdu3ARY8xvK5N/O23pBQLJyZfi2oRWiiVyc8ILbBsSmxOKJiJj9xrdpyCuzcVJ3aktGelXjtKfVo24tcX2vayvmRW9jXg2+e3Rr8yhhIa9qhDqevO1Hdw9v6C/s99O0t79EyA3IUpnDJWhDNXtktPKxH3ayGmruxcGHG4ms1IzVejWl7GqPxi1WvEKP9a1Wv8BXR9SB0=
HFQKTfngcWE5CbrA